课题基金 / 基金详情

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE
吡格列酮 PKS 导致肝功能受损
批准号:
6281022
负责人:
STEVEN SCHENKER
金额:
$1.49万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
吡格列酮,一种正在开发的用于治疗非胰岛素 依赖性糖尿病,通过激活后受体改善高血糖 胰岛素受体的阶段。 口服后,吡格列酮 集中在肝脏中代谢;这项研究的目的是 评价肝功能受损对 吡格列酮在尿液和血清中的药代动力学。 这项研究将 评价吡格列酮在以下受试者中的药代动力学变化 已知肝损害。
英文摘要
Pioglitazone, a drug being developed for the treatment for non-insulin dependent diabetes, improves hyperglycemia by activating the post-receptor phase of the insulin receptor. After oral administration, pioglitazone is concentrated in the liver where it is metabolized; this study is designed to evaluate the effect impaired hepatic function has on the pharmacokinetics of pioglitazone in urine and serum. The study will evaluate changes in the pharmacokinetics of pioglitazone in subjects with known hepatic impairment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金